Foundayo (Orforglipron) – What It Does, What It Costs, and How to Access It

The FDA has approved Eli Lilly’s orforglipron as Foundayo, the first small-molecule GLP-1 receptor agonist pill for obesity with no food or water restrictions. Foundayo is a prescription medicine, not an over-the-counter medicine, and is available only through healthcare providers and pharmacies.

Eli Lilly, a medicine company turning science into practical treatments for obesity and diabetes, developed Foundayo to expand options for adults with obesity or overweight with related health conditions.

Here is what the clinical evidence shows, what it costs, and how patients can access it in the US and UK. Foundayo is Lilly’s second FDA-approved obesity medication, following the approval of another GLP-1 medication.

What Is Foundayo by Eli Lilly?

On 1 April 2026, the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron), an FDA-approved obesity medicine developed by Eli Lilly and Company to treat obesity and overweight adults with weight-related medical problems or weight-related complications. The approval makes Foundayo the only GLP-1 receptor agonist pill for weight loss that can be taken at any time of day, without restrictions on food or water intake.

Foundayo is a new weight loss pill that helps people lose excess body weight and reduce excess body weight.

Unlike other GLP-1 medications currently available, which are either injectable or, in the case of the recently approved Wegovy pill, must be taken on an empty stomach, Foundayo is a once daily oral pill, a once daily pill, and a daily pill designed for flexibility and ease of use. As Lilly’s chair and CEO, David A. Ricks noted, it is “obesity care designed for the real world.”

Orforglipron was originally discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. It is a small-molecule (non-peptide) GLP-1 receptor agonist, meaning it mimics the action of the body’s natural GLP-1 hormone to reduce appetite and body weight, but in a pill form that does not require the complex formulation of peptide-based medicines. Foundayo delivers meaningful weight loss and meaningful weight loss for people living with excess body weight.

A Historic Approval

The approval is notable not only for the medicine itself, but for the speed at which it was achieved. Foundayo received its approval just 50 days after filing, 294 days ahead of its original PDUFA (Prescription Drug User Fee Act) target date of 20 January 2027, making it the fastest approval of a new molecular entity (NME) since 2002.

The approval was granted under the FDA Commissioner’s National Priority Voucher (CNPV) pilot programme, launched in 2025 to expedite review of medicines addressing critical national health priorities. Foundayo is the first NME to be approved under the programme, and represents the fifth approval overall under the CNPV initiative.

FDA Commissioner Martin Makary, M.D., M.P.H. described the approval as demonstrating what the agency can achieve when “we eliminate delays and prioritise fast and thorough work.” The acting CDER Director, Tracy Beth Høeg, M.D., Ph.D. added that the review team delivered a thorough benefit-risk analysis while taking months off the standard review timeline.

Clinical Evidence: The ATTAIN Programme

The approval was supported by the ATTAIN Phase 3 clinical development programme, which enrolled more than 4,500 participants across two large global registration trials. These innovative clinical trials were designed to provide strong scientific evidence for Foundayo’s role in chronic weight management.

ATTAIN-1 was a 72-week, randomised, double-blind, placebo controlled trial comparing orforglipron to placebo in 3,127 adults with obesity or overweight without diabetes, conducted across the U.S., Brazil, China, India, Japan, South Korea and several other countries. The primary objective was to demonstrate that orforglipron is superior to placebo in body weight reduction after 72 weeks. Participants taking the highest dose of Foundayo who remained on treatment experienced a body weight change with an average loss of 27.3 pounds (12.4%) compared with 2.2 pounds (0.9%) on placebo. Across all participants in the trial regardless of adherence, those taking Foundayo achieved a body weight reduction averaging 25 pounds (11.1%) versus 5.3 pounds (2.1%) on placebo.

ATTAIN-2 enrolled over 1,600 participants with obesity or overweight and type 2 diabetes. Foundayo demonstrated statistically significant and clinically meaningful reductions in body weight versus placebo at 72 weeks. Across all doses in both trials, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.

Dr Deborah Horn, director of the Centre for Obesity Medicine at UTHealth Houston, summarised the clinical significance: Foundayo “delivered an average of 12.4% weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day.”

Dosing and Administration

Foundayo is available as oral tablets in the following strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. The dosing regimen follows a graduated titration schedule, beginning with a starting dose of 0.8 mg once daily:

• Starting dose: 0.8 mg once daily
• Increase to 2.5 mg after at least 30 days
• Increase to 5.5 mg after a further 30 days
• Further titration to 9 mg, 14.5 mg, or 17.2 mg based on response and tolerability, with at least 30 days at each level

Tablets should be swallowed whole and must not be broken, crushed, or chewed. Foundayo must be used in combination with a reduced-calorie diet and increased physical activity. Crucially, it can be taken with or without food, at any time of day, a key practical differentiator.

Safety Profile and Warnings

The most commonly reported side effects in clinical trials were nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, fatigue, belching, heartburn, gas, and hair loss. These are typical of the GLP-1 drug class. Constipation, diarrhea, vomiting, and indigestion are common side effects. Gastrointestinal side effects such as diarrhea, vomiting, indigestion, and stomach pain should be monitored closely.

Foundayo carries a boxed warning for thyroid C-cell tumours, including thyroid cancer. It must not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Additional warnings and precautions include:

• Pancreatitis (inflammation of the pancreas), which may present as severe pain or severe stomach problems requiring immediate medical attention
• Severe gastrointestinal reactions
• Acute kidney injury due to dehydration, which may occur as a result of diarrhea, nausea, and vomiting
• Hypoglycaemia (low blood sugar), particularly when used with insulin or sulphonylureas
• Hypersensitivity reactions, including the risk of a serious allergic reaction such as swelling of the face, lips, tongue, or throat
• Diabetic retinopathy in patients with type 2 diabetes
• Acute gallbladder disease, as gallbladder problems have been reported in some people using Foundayo
• Risk of pulmonary aspiration during general anaesthesia or deep sedation

Debilitating immune system disorders are also a consideration in the context of obesity treatment complexity and accessibility.

As a small-molecule drug (unlike peptide-based GLP-1s), there was some concern prior to approval about potential liver toxicity, given that small molecules are metabolised hepatically. However, orforglipron did not show liver risks in clinical trials.

Foundayo should not be used in combination with another GLP-1 receptor agonist. Women of childbearing age should note that Foundayo may affect the absorption and effectiveness of birth control pills; alternative contraception is recommended for 30 days after starting Foundayo and after each dose increase, and backup contraception may be needed.

Pricing and Availability

Foundayo will initially be available in the United States via LillyDirect, Lilly’s direct-to-patient platform, with prescriptions accepted immediately and free home delivery beginning 6 April 2026. Foundayo will start at $25 per month with commercial insurance and $149 for self-pay through LillyDirect. Regular prices for a 1-month supply are $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg. Broad availability through U.S. retail pharmacies and telehealth providers will follow shortly.

Pricing is structured as follows:

• Commercially insured patients: as little as $25 per month with the Foundayo savings card and commercial insurance
• Self-pay (cash price): starting at $149 per month for the lowest dose, with regular prices up to $349 per month depending on dosage
• Medicare Part D: eligible patients may access Foundayo for $50 per month, beginning as early as 1 July 2026

Lilly has also submitted orforglipron for regulatory approval for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each market following approval.

Weight Loss Competitive Landscape

Foundayo enters an increasingly competitive oral GLP-1 market. Novo Nordisk received FDA approval for an oral version of semaglutide (Wegovy pill) in December 2025 and has seen rapid early adoption, giving it a head start over Lilly. However, the two products differ in an important practical respect: the Wegovy pill must be taken in the morning at least 30 minutes before food or drinks other than water, a restriction that many patients find burdensome. Foundayo carries no such requirement.

In terms of clinical efficacy, the Wegovy pill produced approximately 13.6% weight loss in its 64-week Phase 3 trial, slightly above Foundayo’s 11.2% in its 72-week study. Novo has also argued that its pill benefits from the long safety track record of injectable semaglutide, which carries a cardiovascular risk reduction indication.

On pricing, following Novo’s decision to launch its pill at up to $299 per month for self-pay patients, Lilly adjusted its pricing to match, having originally indicated higher cash prices. Analysts view orforglipron as a significant growth catalyst for Lilly, especially given broader market interest in non-injectable weight-loss treatments.

UK MHRA Regulatory Approval

As of April 2026, Foundayo (orforglipron) is not yet approved for use in the United Kingdom. Before it can be prescribed or dispensed by any UK pharmacy, clinic, or online provider, whether privately or through the NHS, it must receive a formal marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA).

Lilly confirmed that it submitted orforglipron for regulatory review for weight management to global regulatory agencies in 2025, with a submission for type 2 diabetes anticipated in 2026. The UK is expected to be among the first countries to receive a marketing authorisation decision, and UK availability, initially via the private sector, could follow in 2026 if the MHRA review proceeds on schedule.

Any website or service claiming to prescribe or supply orforglipron in the UK prior to MHRA approval is operating outside of the regulatory framework. Patients should exercise caution and only obtain weight management medicines from regulated, authorised providers.

The MHRA Review Process

The MHRA is responsible for evaluating the safety, quality, and efficacy of all medicines marketed in Great Britain. Following a regulatory submission, the agency conducts a full scientific assessment of the clinical data package, in orforglipron’s case, drawing on the extensive Phase 3 ATTAIN programme and any additional supporting studies. The standard MHRA review timeline for a new active substance is typically 210 days from validation of submission, though this can vary depending on the complexity of the data and whether expedited pathways apply.

The MHRA operates independently from the European Medicines Agency (EMA) following the UK’s departure from the EU. It has, however, established reliance procedures that allow it to take into account assessments conducted by comparable regulators, such as the FDA, to expedite its own review. Given Foundayo’s historic FDA approval, there is a reasonable basis to expect that the MHRA will draw upon the FDA’s robust scientific review in its own assessment, which could support a faster-than-standard decision timeline.

Private Availability First, Then the NHS

As has been the pattern with other GLP-1 weight management medicines in the UK, including Wegovy (semaglutide) and Mounjaro (tirzepatide), orforglipron is expected to become available through private prescribing channels first, following MHRA approval. This means patients with private healthcare or willing to pay out of pocket may be able to access it before any NHS commissioning is in place.

For NHS availability, a separate assessment by the National Institute for Health and Care Excellence (NICE) in England and equivalent bodies in Scotland (SMC), Wales (AWMSG), and Northern Ireland would be required. NICE appraisals evaluate clinical and cost-effectiveness; a favourable appraisal results in a recommendation to the NHS to commission the medicine. Given the typical NICE appraisal timeline, NHS prescribing of orforglipron is not expected before 2027 at the earliest, even if MHRA approval is secured in 2026.

UK Pricing: What to Expect

No official UK price has been announced for orforglipron. However, Foundayo’s formulation as a small-molecule tablet carries structural pricing advantages worth noting. Unlike peptide-based injectable GLP-1 medicines such as Wegovy or Mounjaro, small molecules are generally simpler and cheaper to manufacture at scale. They also do not require cold-chain storage or distribution infrastructure, reducing logistical costs throughout the supply chain.

Based on the current private pricing of comparable GLP-1 treatments in the UK, market observers suggest that private prescriptions for orforglipron could fall in the region of £100–£300 per month, though this is speculative ahead of any formal UK pricing announcement. Lilly has also demonstrated a willingness to price competitively in the U.S. market in response to rival launches, which may inform its UK commercial strategy.

For NHS patients, any funded price would be subject to separate commercial negotiations between Lilly and NHS England, guided by the outcome of the NICE appraisal and the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG, formerly VPAS).

Supply Confidence: A Manufacturing Advantage

One of the most significant practical advantages of orforglipron over injectable GLP-1 therapies is its manufacturing scalability. The UK has experienced supply shortages of both Wegovy and Mounjaro since their launches, creating significant demand that could not be met and delaying treatment for many patients. As a small molecule produced via conventional tablet manufacturing, Lilly has expressed confidence in its ability to launch orforglipron worldwide without supply constraints, a reassurance that will be closely watched by NHS commissioners and private prescribers alike.

United States Patient Assistance and Affordability Support

Lilly has structured several affordability pathways for Foundayo, recognising that cost and access remain significant barriers to treatment for people living with obesity. These are delivered primarily through LillyDirect, Lilly’s direct-to-patient pharmacy platform.

Foundayo Savings Card, Commercially Insured Patients (with Coverage)

Eligible patients who have commercial drug insurance that covers Foundayo may pay as little as $25 per month using the Foundayo Savings Card. To qualify, patients must meet all of the following criteria:

• Have been prescribed Foundayo for an FDA-approved use
• Be enrolled in a commercial drug insurance plan
• Not be enrolled in any state, federal, or government-funded healthcare programme, including Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, or TRICARE®/CHAMPUS
• Be a resident of the United States or Puerto Rico
• Be 18 years of age or older

Monthly savings are subject to maximum limits, and the card expires on 31 December 2026. Card eligibility and terms may be amended by Lilly at any time without notice. The Savings Card is not insurance.

Self-Pay and Commercially Insured Patients Without Coverage

For patients without insurance coverage for Foundayo, or those opting to pay directly without using insurance, Lilly has established the following self-pay price points through the Foundayo Self-Pay Savings Card Programme:

• 0.8 mg dose: as low as $149 per month (maximum monthly saving of up to $520)
• 2.5 mg dose: as low as $199 per month (maximum monthly saving of up to $470)
• 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg doses: as low as $299 per month (maximum monthly saving of up to $370)

For the two highest doses (14.5 mg and 17.2 mg), the $299 monthly price reflects the Foundayo Self-Pay Journey Programme, which applies to patients who continually renew their prescription. If a prescription is not refilled within 45 days, standard pricing applies ($349/month for these doses).

Patients enrolled in an Alternate Funding Programme (AFP), where an insurance plan directs patients to seek specialty drug coverage through an alternate vendor, are not eligible for the self-pay savings programme. Patients should confirm their eligibility before enrolment.

Medicare Part D Patients

Eligible Medicare Part D beneficiaries may be able to access Foundayo for approximately $50 per month, beginning as early as 1 July 2026, under plan provisions negotiated between Lilly and Medicare coverage programmes. Government beneficiaries are excluded from the commercial Savings Card Programme; the Medicare pathway is separate.

How to Access Foundayo via LillyDirect

LillyDirect provides patients with a streamlined route to Foundayo, whether they are commercially insured or self-paying. The process works as follows:

1. Ask your doctor to send a prescription to LillyDirect Pharmacy (NPI: 1912889320 | NCPDP: 1574056)
2. A pharmacy partner will reach out to confirm your details, explore any available savings, and guide you through payment options
3. Choose home delivery (free) or in-store pickup at a participating retail location
4. Any eligible savings card is automatically applied where applicable
5. Assistance with prior authorisations is available as needed

LillyDirect currently partners with Prescryptive® and Amazon Pharmacy as third-party pharmacy fulfillment providers. Shipping through LillyDirect began on 6 April 2026, with broad availability through U.S. retail pharmacies and telehealth providers following shortly after.

For further information about pricing and patient support options, visit foundayo.lilly.com or contact Lilly Support Services™ on 1-800-LillyRx (1-800-545-5979).

Summary

Foundayo (orforglipron) represents a meaningful step forward in obesity pharmacotherapy, bringing together the clinical efficacy of the GLP-1 drug class with the convenience of a daily oral tablet that patients can take freely, at any time, without dietary preparation. Its rapid approval under the CNPV programme underscores the FDA’s recognition of obesity as a national health priority, and Lilly’s ambition to broaden access to effective treatment.

For patients, prescribers, and pharmacy professionals, Foundayo is expected to become an important tool in the management of obesity, with broad availability across U.S. retail pharmacies and telehealth platforms imminent, and international regulatory submissions already in progress.

This article is intended for informational purposes only and is based on publicly available regulatory and press information. It does not constitute medical advice. Prescribers and patients should consult the full Prescribing Information and Medication Guide for Foundayo before use.